Rani Therapeutics Holdings, Inc.
RANI Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$0.61
KIRA · Stoqly’s AI analyst, in plain words
- Rani Therapeutics Holdings, Inc. had $1.6M of revenue in fiscal 2025, up 58.9% on the year before. Over five years, revenue changed +28.7% a year on average.
- Its operating margin was −2,346.0%, up 2,840.2 pts: of every 100 in sales, about −2,346 is left after running the business.
- Rani Therapeutics Holdings, Inc. lost $29.7M in fiscal 2025.
- Free cash flow was −$18.8M in fiscal 2025, −1,151.4% of revenue.
- Rani Therapeutics Holdings, Inc. has $18.6M more cash than debt.
Market cap
$114M
P/E
—
Revenue
$1.6M
Net income
−$29.7M
Free cash flow
−$18.8M
Operating margin
−2,346.0%
Rani Therapeutics Holdings, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+58.9%
Yes. Sales grew 58.9% last year.
Does it make a profit?
−1,817.1%
No. It lost money last year.
Does profit turn into cash?
−1,151.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Rani Therapeutics Holdings, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Rani Therapeutics Holdings, Inc.
- CIK
- 0001856725
Rani Therapeutics Holdings, Inc. · RANI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.7M | $0.0M | $0.0M | $1.0M | $1.6M |
| Revenue growth | 488.1% | −100.0% | — | — | 58.9% |
| Operating margin | −1,899.1% | — | — | −5,186.2% | −2,346.0% |
| Net income | −$8.3M | −$30.6M | −$34.0M | −$30.0M | −$29.7M |
| Net margin | −306.6% | — | — | −2,920.0% | −1,817.1% |
| Diluted EPS | −$0.43 | −$1.28 | −$1.33 | −$1.05 | −$0.45 |
| Cash | |||||
| Cash from operations | −$32.2M | −$46.5M | −$51.2M | −$35.5M | −$18.7M |
| Capital expenditure | $0.5M | $1.6M | $1.2M | $0.3M | $0.1M |
| Free cash flow | −$32.8M | −$48.1M | −$52.5M | −$35.8M | −$18.8M |
| FCF margin | −1,205.4% | — | — | −3,479.0% | −1,151.4% |
| Share count change | — | 22.1% | 7.1% | 11.8% | 131.9% |
| Debt and strength | |||||
| Cash and short-term investments | $117M | $126M | $5.9M | $3.8M | $18.6M |
| Debt incl. finance leases | $0.0M | $30.0M | $30.0M | $25.0M | $0.0M |
| Shareholders' equity | $47.4M | $36.9M | $12.9M | $2.0M | $33.0M |
| Current ratio | 45.3x | 21.0x | 6.4x | 1.5x | 4.2x |
| Interest coverage | −110.7x | −59.2x | −13.0x | −10.6x | −13.3x |
| Returns and quality | |||||
| Return on capital | — | — | −141.1% | −181.3% | −210.3% |
| Return on equity | — | −72.6% | −136.6% | −404.1% | −169.6% |
| Return on tangible equity | −17.6% | −83.0% | −264.0% | −1,506.9% | −89.9% |
| Piotroski F-score | 4 | 0 | 0 | 1 | 4 |
| Altman Z'' | 22.0 | 1.9 | −6.5 | −17.1 | −5.2 |
Insiders bought, 12 months
$0.1M
2 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Rani Therapeutics Holdings, Inc. · RANI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.61 a share, the company is worth $114M.
Source: SEC EDGAR XBRL filings (CIK 0001856725). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.